Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP T cells in pediatric solid tumors
NCT02932956Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2018
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GAP T cells in liver cancer, sponsored by Baylor College of Medicine. Primary endpoint: Number of Patients with Dose Limiting Toxicity at 6 weeks. Started Dec 2018; status: active, not recruiting.
02
Drugs
GAP T cells
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT02932956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932956.